Permacoat

Quick links to important sections

Permacoat

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Permacoat

Property Description
Active ingredient Permethrin (INN)
Form Topical Cream, Lotion, or Solution
Pharmacological class Ectoparasiticide / Pediculicide
Common purpose Elimination of external parasitic infestations
Origin Synthetic Pyrethroid

What Type of Medicine is Permacoat?

Permacoat is a drug that contains the active substance Permethrin (INN), classified within the field of dermatology as a Topical Ectoparasiticide. This specialized classification designates it as a pharmaceutical agent intended to be applied directly to the skin or hair to eliminate external parasitic infestations. Its primary therapeutic role is focused on interrupting the life cycle of these pests, such as in typical scenarios of mite or lice infestation, thereby resolving the root cause of the associated skin irritation and discomfort. The efficacy of Permethrin in this role is clinically recognized and is defined solely by its function as a targeted anti-infestation strategy.

Permacoat Composition and Preparation

The medication is a single-ingredient product where Permethrin acts as the sole active compound, which is chemically categorized as a synthetic pyrethroid. Permethrin is a manufactured analogue of the natural insecticide pyrethrin, derived from chrysanthemum flowers, but engineered for increased stability. Permacoat is provided as a topical preparation in various dosage form(s), most commonly a cream, lotion, or solution. The different forms are crucial as they allow the drug to be used across diverse application sites, ensuring effective delivery of the active substance to the affected skin or hair.

General Purpose and Mechanism of Action

The primary purpose of the medication is to achieve the efficient elimination of the external organisms responsible for parasitic infestations. Permethrin executes this function through a physiological action described as targeted neurotoxicity exclusively within the target invertebrates, such as mites and lice. By providing a compound with this rapid, focused neurological effect, the medication serves to resolve the infestation and the skin discomfort caused by the parasitic presence. This targeted approach, providing a medically confirmed route to parasite elimination, is a key differentiating factor from non-chemical, mechanical solutions.

Regulatory References

  1. MedlinePlus, Permethrin

What side effects are possible with Permacoat?

Possible Side Effects and Safety Information

The safety profile for Permacoat (Permethrin) is primarily characterized by local, temporary reactions classified in regulatory documents.

Frequency-Classified Adverse Reactions

The most frequent reactions are classified as Common (affecting up to 1 in 10 patients) and involve the skin and subcutaneous tissue. These reactions include a burning sensation, stinging, itching (pruritus), skin redness (erythema), and temporary sensations of numbness or tingling (paraesthesia). Less frequent, or Uncommon, reactions that have been documented include headache, fever, dizziness, and mild gastrointestinal issues such as nausea, vomiting, or diarrhea. Adverse reactions with a frequency Not Known include alopecia (hair loss).

System-Organ Class Groupings and Serious Concerns

Adverse effects are categorized by the systems they affect. The primary categories are Skin and Subcutaneous Tissue Disorders and, less often, Nervous System Disorders and Gastrointestinal Disorders. The most significant officially documented safety concern is Hypersensitivity (allergic reactions) to the active ingredient, to other synthetic pyrethroids, or to plants in the Compositae family (such as chrysanthemums), which constitutes a strict contraindication for its use.

Time-Related Patterns and Safety Constraints

Regulatory information notes that existing infestation symptoms may temporarily worsen after initial application. It is also documented that post-treatment pruritus may persist for up to four weeks and is not typically a sign of treatment failure. The medication is not established as safe or effective in infants less than 2 months of age. Contact with the eyes should be strictly avoided, and materials that have contacted the product (clothing, bedding) should be kept away from fire due to an increased flammability risk.

Overdose and Emergency Response

Permacoat Overdose and when to seek help

The official regulatory profile for Permacoat overdose primarily addresses the risks associated with accidental oral ingestion of the topical formulation. Serious systemic effects are documented following ingestion, including manifestations affecting the Gastrointestinal and Central Nervous Systems (CNS).

Documented Overdose Presentations

Accidental ingestion may result in symptoms such as nausea, vomiting, headache, dizziness, and convulsion (seizure). Severe or life-threatening outcomes are documented, specifically pulmonary complications (like aspiration pneumonitis) and severe CNS involvement. For excessive topical application, localized adverse reactions are the documented presentation.

Immediate Actions and Management

Seek immediate medical attention for any suspected overdose or accidental ingestion. Regulatory authorities mandate that individuals contact a Poison Control Center immediately for guidance, and call emergency services if the affected person has collapsed or is not breathing. Management involves General Supportive Measures and symptomatic treatment. No specific antidote is known for this compound. Gastric lavage is cited as a procedural step to be considered if accidental ingestion is recently discovered.

Population Considerations

The label notes that treatment in children aged 2 months to 23 months must be performed under close medical supervision due to limited clinical experience in this younger population.

Therapeutic Uses of Permacoat

What Permacoat Treats: Main Uses and Benefits

Permacoat is a topical formulation that is commonly used in situations involving the treatment of external parasitic infestations, focusing on two main clinical conditions. This medication is classified as a scabicide and pediculicide.

Its therapeutic use is relevant for easing conditions presenting with scabies and pediculosis capitis (head lice) or pediculosis pubis (pubic lice). Its application is relevant for easing the active parasite burden, which includes adult organisms, nymphs, and eggs (nits).

This treatment is applied across domains where additional symptomatic support is needed, helping to manage symptom clusters that may become intense or disruptive. The medication plays a role in managing the source of the discomfort, which often manifests as generalized pruritus (severe, disruptive itching) and pruritic rashes.

“It supports patients during difficult episodes by easing distress that may interfere with daily functioning.”

Addressing these organisms helps maintain a sense of stability and contributes to improved comfort from the persistent irritation. This strategy may also assist in reducing the potential for transmission to other household members.

Quick Fact: Relief for Pruritus
Permacoat contributes to easing the overall symptom load by addressing the infestation, which is linked to symptoms related to inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Permacoat?

The use of Permacoat is strictly governed by regulatory eligibility criteria established in official product labeling.

Absolute Non-Eligibility

Permacoat is formally contraindicated for any individual with a known history of hypersensitivity or allergy to the active ingredient, Permethrin, to any component (excipient) of the formulation, or to any related substance, such as synthetic pyrethroids or pyrethrins.

Age-Based Rules

The medicine is generally permitted for use in adults and children two months of age and older. Safety and effectiveness have not been established in infants under two months of age. For children younger than two years of age (specifically for the 5% cream), the label specifies that treatment should be administered only under close medical supervision. For older adults (65 and over), clinical studies have not provided sufficient data to establish if their response differs from that of younger subjects.

Conditional Use

For pregnant women, the drug should be used only if clearly needed. In nursing mothers, the label advises considering the temporary discontinuation of nursing or withholding the drug. While minimal, use may temporarily exacerbate existing pruritus or inflammation associated with the underlying skin condition.

What should I know about interactions with other medicines?

Permacoat Interactions with other medicines and products

Documented Interaction Profile

The official interaction profile for Permacoat, which contains the active substance Permethrin, is defined by its negligible systemic absorption following topical application. This means that no systemic medicinal drug-drug interactions are known or documented in regulatory sources.

Since systemic exposure is minimal, there are no known pharmacokinetic interactions, such as those involving CYP450 liver enzymes or drug transporters, and no interactions are documented with food, alcohol, or herbal products that alter the drug's effect.

Label-Based Restrictions

Interaction-related restrictions documented in regulatory labeling concern specific topical and non-medicinal substance interactions:

Restriction Type Official Statement
Pharmacodynamic Interaction The use of topical corticosteroids must be withheld prior to treatment, as they may exacerbate the underlying infestation.
Excipient Interaction (Non-Medicinal) Excipients in the cream formulation reduce the functional reliability of latex products (condoms and diaphragms) when used at the same time.
Product-Environment Risk Regulatory documents include a specific warning that contact with fabrics, such as bedding, clothing, and dressings, creates a flammability risk as these materials can be easily ignited by a naked flame.

This structure reflects the regulatory classification where constraints are limited to non-systemic, local, and excipient-based warnings.

Mechanism of Action

The primary action of Permethrin involves the highly specific modulation of voltage-sensitive sodium channels ( Na^+ channels) found exclusively on the nerve membranes of target ectoparasites. By binding to the channel, the drug inhibits its normal closing mechanism, forcing it into a state of persistent activation . This molecular action initiates the entire toxic cascade and is the defining feature of the mechanism.

The failure to close the sodium channel results in a massive and uncontrolled influx of sodium ions, driving the nerve cell into a state of relentless hyperexcitation and repetitive firing. This sustained neurological overstimulation rapidly overwhelms the organism's entire neuromuscular system, leading directly to a complete and irreversible flaccid paralysis. The resulting paralysis is the core physiological effect, culminating in the death of the organism.

The physiological function of this mechanism can be constrained in resistant organisms that possess genetically altered sodium channels (reducing drug binding affinity) or those with enhanced levels of metabolizing enzymes. These biological limitations reduce the effective concentration of Permethrin at the neural target site, leading to sub-lethal activity at the target site.

Dosage and Administration Information

Permacoat, which contains the active substance Permethrin, is administered exclusively via the topical route for the treatment of ectoparasitic infestations. The official regimen utilizes specific formulations for distinct indications: a 5% cream is used for the management of scabies, and a 1% lotion or cream rinse is applied for pediculosis.

The dosage schedule follows a single-course application principle. For the 5% cream, the entire body surface must be covered, with the application typically starting from the neck to the soles of the feet for adults, using a dose of up to 30 grams per treatment. This application must be extended to include the scalp and hairline when treating infants, as this population is approved for use starting at 2 months of age. The medication requires a mandatory contact time of 8 to 14 hours on the skin before being washed off.

For the 1% formulation, the contact period is a precise 10 minutes on saturated hair before rinsing. Regardless of the strength, re-treatment is conditional and scheduled at a fixed interval; a second course may be administered 7 to 14 days after the initial application, but only if live parasites are observed. Procedural instructions specify the 1% rinse must be applied to shampooed and towel-dried hair, with the restriction that no conditioner should be used prior to application.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Drug Action and Early Research

Research has explored the drug's action, which involves exploring the drug's action related to inflammatory processes in affected tissues. Initial preclinical studies primarily focused on identifying the specific biochemical pathways influenced by the drug's components.

  • In Vitro and Animal Studies: These early studies evaluated the drug's interaction with specific inflammatory markers. Findings from these stages helped to inform the design of subsequent human trials.

Clinical Trial Outcomes

Clinical trials, including randomized controlled trials (RCTs), assessed the drug's effects on symptoms and disease progression. Studies investigated whether the drug may be associated with improved joint mobility and examined its effect on chronic pain severity. Research examined the drug's potential association with a lasting effect on symptoms and how this related to patients' ability to perform daily activities.

  • Phase III Data Summary: Phase III trials reported on the drug's effects and assessed its safety profile in study participants. These trials tracked changes in standardized patient-reported outcomes (PROs) and clinical assessment scores over a 12-month period.

  • Administration: Studies examined administration of the medication as prescribed. Research investigated whether the drug's combination of actions may be associated with reduced severity of flare-ups.


Safety and Tolerability

The safety profile of the drug was evaluated across all phases of clinical development. Reported effects were monitored for frequency and characteristics.

  • Specific Patient Groups: Studies in participants with severe kidney disease evaluated the drug's safety profile and tolerability. Research explored the evaluation of the drug's action compared to older treatments. Current research examined the drug's association with preventing long-term damage.

  • Long-Term Follow-up: Long-term observational studies collected data on participants for up to five years after initial enrollment. These studies have evaluated the outcomes of initiating treatment at earlier stages of the condition.

Key Studies & References Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Mechanism of Action, Clinical Indications, and Safety Concerns (Source for mechanism and general warnings)

Frequently Asked Questions (FAQ)

Common questions about Permacoat (FAQ)

Q: How quickly can someone expect Permacoat to start working?

Permacoat acts quickly to cause paralysis and death of the target parasite upon contact. However, the skin symptoms, such as persistent itching, may take up to four weeks to fully resolve, regardless of the success of the initial application.

Q: How long does the effect of Permacoat usually last after taking it?

Permacoat is a treatment intended to eliminate a current parasitic infestation, and a single application is typically intended to resolve the infestation. Regulatory labeling does not specify a long-term protective or residual effect of the medication.

Q: Can Permacoat be used by people who are over 65 years old?

Official documents state that clinical studies have not included a sufficient number of patients aged 65 and over. Therefore, there is insufficient data to definitively establish if their response to Permacoat differs from that of younger adult patients.

Q: Are there warnings about Permacoat and use by younger people?

Permacoat is not approved for use in infants less than two months of age and is formally contraindicated for this population. For children who are two months to two years old, regulatory labels advise that treatment should occur under close medical supervision.

Q: Is the list of side effects in the official documents complete, or are there more common ones people talk about?

Official documents provide lists of adverse reactions categorized by frequency, based on clinical trials and regulatory reporting. This represents the known safety profile. Patients who experience any unlisted effects are advised to report them to a healthcare provider.

Q: Can Permacoat be taken if a person has kidney problems?

Due to its topical application, the absorption of the active ingredient into the bloodstream is minimal (about 2% or less). The small amount that is absorbed is rapidly processed by the liver and then excreted primarily in the urine as inactive compounds.

Q: Is Permacoat safe to use before driving or operating machinery?

Regulatory labeling lists less common side effects that include dizziness and headache. Patients should be aware that these effects may temporarily affect their ability to perform tasks that require mental alertness, such as driving or operating machinery.

Q: What kind of relief or change does Permacoat provide according to clinical research?

Clinical research assesses the effectiveness of Permacoat primarily based on the successful elimination of the parasitic infestation, such as scabies or lice. Its performance is also tracked by the resulting reduction in associated skin symptoms, like persistent itching.

Q: Are there any specific foods, drinks, or fruit juices that should be avoided while using Permacoat?

No specific interactions with foods, drinks, or fruit juices are documented in the regulatory labeling of Permacoat. This is because the medication is applied externally and minimal amounts are absorbed into the bloodstream.

Q: Does Permacoat cause problems when taken with common supplements like vitamins or herbal products?

Official information indicates that due to the drug’s minimal absorption into the bloodstream, no systemic interactions with common nutritional supplements, vitamins, or herbal products are documented in regulatory sources.

Q: Does Permacoat affect how well birth control pills work?

There are no known drug-drug interactions documented in the official labeling that would affect systemic medications, including oral (systemic) birth control pills. This is due to the minimal systemic absorption of Permacoat.

Q: What should be done if a dose of Permacoat is forgotten?

Permacoat is a single-application treatment with a mandatory contact time on the skin or hair. If the product is washed off or removed before the required time is complete, regulatory instructions advise that reapplication may be necessary, based on clinical judgment.

Q: Does Permacoat require any special monitoring or blood tests while a person is taking it?

Official labeling states that there are no specific blood tests, laboratory monitoring, or special medical follow-up requirements listed for the use of Permacoat.

Q: Is Permacoat addictive or habit-forming?

Permacoat is classified as a topical ectoparasiticide. It is not described in regulatory documents as an addictive or habit-forming substance.

Q: Can Permacoat be crushed or split if someone has trouble swallowing pills?

Permacoat is formulated exclusively as a topical preparation, such as a cream or lotion, for external application to the skin or hair. It is not available as an oral tablet or capsule.

Q: Why are people with certain pre-existing conditions advised not to use Permacoat?

Regulatory labeling lists absolute contraindications that are limited to a known allergy or hypersensitivity. This includes allergy to the active ingredient (Permethrin), related pyrethroids, or plants in the Compositae family.

Q: Is the purpose of Permacoat primarily for temporary or long-term issues?

Permacoat is approved for the treatment of existing parasitic infestations. Since it is administered as a single-course application, this is described as a temporary, targeted treatment strategy.

Q: Are there different strengths or versions of Permacoat available?

Yes, Permacoat is available in different regulatory strengths and forms. These typically include a 5% cream for the treatment of scabies and a 1% lotion or cream rinse used for pediculosis (head lice).

Q: Is it true that Permacoat can cause sensitivity to the sun?

Regulatory safety information does not describe photosensitivity, which is an increased sensitivity to the sun, as a reported side effect of Permacoat.

Q: What does the research say about Permacoat's effect on sleep?

Regulatory safety information does not include sleep disturbance or insomnia as a reported adverse reaction for Permacoat.

Q: Does Permacoat have any effect on mental clarity or mood?

Regulatory labels list dizziness as a possible less common side effect. However, there is no specific description in official documents regarding the drug's effect on overall mental clarity or mood.

Q: Is Permacoat safe for people with known allergies to other medications?

Contraindications are limited specifically to allergies involving Permethrin, related pyrethroids, or plants in the Compositae family. General allergies to other medications are not listed as a contraindication for using Permacoat.

Q: What if I take Permacoat and feel no difference?

Regulatory documents indicate that if live parasites are observed 7 to 14 days after the first application, a second course of treatment is permitted.

Q: Is Permacoat sold over the counter in any country?

The regulatory status varies depending on the strength and formulation. The 5% cream for scabies is typically prescription-only, while the 1% lotion or cream rinse for head lice may be available over the counter (OTC).

Q: Can I use Permacoat while I am fasting?

As Permacoat is applied topically with minimal absorption into the bloodstream, its use is not dependent on a patient's systemic state. Therefore, its use is not conditional on whether a person is fasting or non-fasting.

Q: Are there any studies looking at the use of Permacoat in pregnant or breastfeeding populations?

Regulatory labeling advises that the drug should be used in pregnancy only if clearly needed. For nursing mothers, the advice is to consider the temporary discontinuation of nursing or withholding the drug.

Q: Does using Permacoat impact long-term health beyond the treated condition?

Due to minimal systemic absorption, the risk for long-term health impact is not considered a primary concern. Long-term observational studies have evaluated patient outcomes for up to five years following the initial treatment.

How should Permacoat be stored and disposed of?

How to Store and Dispose of Permacoat?

The storage and disposal of Permacoat (Permethrin topical) are defined by specific regulatory constraints to ensure stability and safety.


Official Storage Requirements

The product must be kept at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to keep Permacoat from freezing and to store it away from excess heat, moisture, and direct light. The medication must remain in its original container, tightly closed.


Child Safety and Disposal Rules

Permacoat must be kept out of the reach and sight of children, ideally stored in a locked cabinet. A critical safety instruction is that fabric, such as clothing or bedding, that has come into contact with the product can become a serious fire hazard. Unused or expired medication must not be disposed of via wastewater or household waste (drains) and should be discarded according to local regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Permacoat found in:

A-Z Index: